Ronald Uszenski, MD
Interventional Cardiology · Mooresville, NCNPI 1447230099
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $425,578 of the $494,929 with a category attached, or 86.0%. Johnson & Johnson accounts for 99.2% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $137,561 and has fallen 98.5% since, to $2,013 in 2025. Among interventional cardiology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 584 payments — averaging $847.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$491K
- Boston Scientific$2K
- Amgen$256
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$251
- Novartis$218
- Abbott$200
- plus $922 from 18 others
What the payments were for
- Consulting fees$28,6306%
- Speaking & faculty fees$425,57886%
- Travel & lodging$27,8916%
- Food & beverage$12,8303%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 482 | $491,168 |
| Boston Scientific | 16 | $1,914 |
| Amgen | 8 | $256 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $251 |
| Novartis | 12 | $218 |
| Abbott | 5 | $200 |
| E.r. Squibb & Sons, L.L.C. | 11 | $190 |
| Abiomed | 5 | $137 |
| Pfizer | 4 | $80 |
| Bayer | 4 | $70 |
| Sanofi-aventis U.S. LLC | 3 | $64 |
| Philips North America LLC | 3 | $60 |
| Alnylam Pharmaceuticals Inc. | 2 | $52 |
| Lexicon Pharmaceuticals, Inc. | 2 | $41 |
| Tactile Systems Technology Inc | 1 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Convatec Inc. | 1 | $25 |
| Kestra Medical Technology Services, Inc. | 1 | $25 |
| Edwards Lifesciences | 1 | $25 |
| Cvrx, Inc. | 1 | $22 |
| Bridgebio Pharma, Inc. | 1 | $20 |
| GSK | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$485,131
- WATCHMAN Access System$1,134
- WATCHMAN FLX$311
- Repatha$121
- MitraClip$101
How this compares
$494,929 in reported general payments places this provider in the 95th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 374 | $453,927 |
| XareltoRivaroxaban | 387 | $420,664 |
| EntrestoSacubitril/Valsartan | 77 | $103,075 |
| Repatha SureclickEvolocumab | 86 | $90,739 |
| Praluent PenAlirocumab | 27 | $28,276 |
| MultaqDronedarone Hcl | 14 | $11,028 |
| BrilintaTicagrelor | 11 | $9,408 |
| Flecainide Acetate | 294 | $8,740 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 202 | $4,924 |
| Metoprolol Succinate | 463 | $4,875 |
| Digoxin | 173 | $3,881 |
| Atorvastatin Calcium | 283 | $3,296 |
| Valsartan | 139 | $3,215 |
| SotalolSotalol Hcl | 183 | $2,947 |
| Rosuvastatin Calcium | 215 | $2,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $80 | $453,927374 claims |
| Johnson & JohnsonXarelto | $491,168 | $420,664387 claims |
| NovartisEntresto | $218 | $103,07577 claims |
| Sanofi-aventis U.S. LLCMultaq | $64 | $11,02814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Mooresville
- George AdamsGarner$4.1M
- Paul MahoneyGreenville$1.7M
- Ravish SacharRaleigh$1.6M
- Patrick SimpsonPinehurst$579K
- Oluseun AlliCharlotte$485K
- Matthew CavenderChapel Hill$453K
- Steven FilbyPinehurst$442K
- Naveed RajperStatesville$223K
- Siddhartha RaoCary$223K
- Jan PattanayakAsheville$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.